Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review
Kim Van der Eecken(Ghent University Hospital), Piet Ost(Ghent University Hospital), Bram De Laere(Karolinska Institutet), Jo Van Dorpe(Ghent University Hospital), Valérie Fonteyne(Ghent University Hospital), Alexander W. Wyatt(University of British Columbia), Phuoc T. Tran(University of Chicago Medical Center), Sofie Verbeke(Ghent University Hospital), Nicolaas Lumen(Ghent University Hospital), Edmond M. Kwan(BC Cancer Agency), Matthew P. Deek(Johnson University), Evan W. Warner(Guardant (United States)), Jan Vanwelkenhuyzen(Ghent University)
Cited by 39
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
|Cell|2017|521
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520